Data updated: Mar 10, 2026
METHOCARBAMOL
METHOCARBAMOL
Approved 1974-10-22
42
Indications
--
Phase 3 Trials
51
Years on Market
Details
- Status
- Discontinued
- First Approved
- 1974-10-22
- Routes
- ORAL, IM-IV, INJECTION
- Dosage Forms
- TABLET, SOLUTION, INJECTABLE
Companies
HEATHER Novartis SUPERPHARM ASCOT EUGIA PHARMA GRANULES CHARTWELL MOLECULAR PIONEER PHARMS Aurobindo Pharma WATSON LABS ANI PHARMS PHARMOBEDIENT Baxter SOLVAY PRINSTON INC ROXANE BOSTAL Fresenius Kabi PURACAP PHARM CLONMEL HLTHCARE MONTEREY PHARMS LLC Viatris NYLOS KV PHARM HETERO LABS LTD III AIPING PHARM INC IVAX SUB TEVA PHARMS TABLICAPS Hikma SAGENT PHARMS INC Sun Pharma UPSHER SMITH AM THERAP NAVINTA LLC SOMERSET THERAPS LLC SLATE RUN PHARMA POINTVIEW HLDINGS OXFORD PHARMS ABLE IMPAX LABS INWOOD LABS PUREPAC PHARM Dr. Reddy's MARSAM PHARMS LLC AM REGENT REGCON HOLDINGS GLAND MIKART
Active Ingredient: METHOCARBAMOL
Website: ↗
METHOCARBAMOL Approval History
Loading approval history...
What METHOCARBAMOL Treats
42 FDA approvalsOriginally approved for its first indication in 1974 . Covers 42 distinct patient populations.
- Other (42)
Other
(42 approvals)- • Approved indication (Oct 1974)
- • Approved indication (Feb 1975)
- • Approved indication (May 1975)
- • Approved indication (Jul 1975)
- • Approved indication (Dec 1975)
- • Approved indication (Aug 1976)
- • Approved indication (Aug 1976)
- • Approved indication (Aug 1976)
- • Approved indication (Aug 1976)
- • Approved indication (Aug 1976)
- • Approved indication (Nov 1976)
- • Approved indication (Jan 1977)
- • Approved indication (Mar 1977)
- • Approved indication (Mar 1977)
- • Approved indication (Dec 1977)
- • Approved indication (Oct 1979)
- • Approved indication (Feb 1980)
- • Approved indication (Feb 1980)
- • Approved indication (Jul 1980)
- • Approved indication (Dec 1991)
- • Approved indication (Sep 1994)
- • Approved indication (Jan 2003)
- • Approved indication (Mar 2003)
- • Approved indication (Nov 2009)
- • Approved indication (Oct 2011)
- • Approved indication (Dec 2014)
- • Approved indication (May 2016)Letter
- • Approved indication (Oct 2016)
- • Approved indication (Jan 2017)
- • Approved indication (Feb 2017)
- • Approved indication (Jun 2017)
- • Approved indication (Jul 2017)
- • Approved indication (Jul 2017)
- • Approved indication (Jul 2017)
- • Approved indication (Nov 2017)Letter
- • Approved indication (Apr 2018)
- • Approved indication (May 2018)
- • Approved indication (Oct 2018)
- • Approved indication (Aug 2020)
- • Approved indication (Apr 2021)
- • Approved indication (Jul 2022)
- • Approved indication (Jun 2023)
🔬
Pro Active Pipeline
Ongoing clinical trials by development phase
Loading...
⭐
Pro Key Completed Trials
Completed studies with published results, ranked by significance
Loading...
📊
Trial Timeline
Full development history with FDA approval milestones
Loading...
Understanding FDA Approval Types
| Count | Type | What it means |
|---|---|---|
| - | ORIG | Original approval - drug first enters market |
| - | SUPPL - Efficacy | New indication (new disease/condition approved) |
| - | SUPPL - Labeling | Label text changes (warnings, dosing updates) |
| - | SUPPL - Manufacturing | Production changes (new facility) |
| - | SUPPL - Chemistry | Formulation changes (new dosage strength) |
Green lines in the timeline show ORIG and Efficacy approvals - the clinically meaningful milestones.
METHOCARBAMOL FDA Label Details
ProWant competitive intelligence?
See who's developing similar drugs and track their progress
Data Sources
Data sourced from official FDA and NIH databases. Click links to verify on original sources.